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Background
Women are commonly advised by various sources (including healthcare professionals, the media, or friends and family) against medication use during pregnancy and/or lactation unless the benefits of treating an illness outweigh the risks associated with treatment to both the mother and child. Unfortunately, information supporting medication use in pregnancy and/or lactation and evidence regarding benefits and risks is often lacking, contradictory or difficult to interpret and apply to clinical practice. 1 Medication use during pregnancy and lactation is extremely common, with the majority of women expected to take some form of non-prescription or prescription medication in the antenatal, perinatal (including labour/delivery) and/or postnatal period. 2, 3 These medications are required for the optimal management of pre-existing chronic (i.e. diabetes) or acute (i.e.
urinary tract infection) medical conditions, as well as the management of new conditions associated with pregnancy (i.e. gestational diabetes, nausea and vomiting) or lactation (i.e. mastitis). In a recent Australian study of women attending an antenatal clinic, 40% of women reported a chronic medical condition during pregnancy. 2 This associated burden is likely to increase over time, with a greater number of women entering pregnancy with co-morbidities that require ongoing medical management, or that place them at greater risk of developing pregnancy complications requiring medical management. 4 Existing challenges in decisions are further compounded through a need to consider and understand the impact of physiological changes that occur throughout pregnancy on the pharmacokinetics and pharmacodynamics of medication. 5 In certain situations these may alter a medications therapeutic or toxic effects. 5 Pharmacists practicing in all healthcare settings often represent a key source of information on medication use in pregnancy and/or lactation. Despite this, information related to how pharmacists can specifically contribute towards optimising medication management during pregnancy and lactation remains scarce. Therefore, this pharmacy practice review aims to provide a summary on the role of pharmacists in optimising medication management during pregnancy and lactation, while paying specific focus on highlighting key challenges and importantly, opportunities for greater involvement. It also takes the unique approach of linking areas of greater pharmacist contributions with key components of practice, with the aim that this may provide the impetus for the future development of formal standards of practice in the area.
Decisions Regarding Medication Use
Pregnancy and lactation has a unique effect on decisions relating to medication use.
Medication safety can often be a great source of concern for women and healthcare professionals alike, leading to decisions that can negatively impact on outcomes. Research has demonstrated that pregnant women frequently overestimate the risk of medication use and other exposures during pregnancy. 6 In fact, it is not uncommon for pregnant women to become non-adherent to medications during pregnancy, often owing to misperception of risks associated with their use. 7, 8 These decisions may also stem from a lack of perceived benefit of medication use, rather than safety alone. These concerns are not unique to women. An
Australian survey demonstrated that, over 25% of doctors would instruct their pregnant patients to decrease or discontinue asthma medication during pregnancy where asthma was well controlled by that medication. 9 This is despite knowledge of the potential harmful effects of worsening asthma on perinatal outcomes. 9 Notably, the opposite can also be true, with pregnant women, or indeed healthcare professionals, having a poor understanding of potential risks associated with using particular medications during pregnancy. For example, a survey identified that 26% of pregnant women were unaware of the adverse effects of using NSAIDs during late pregnancy. 10 This highlights the importance of pharmacists in addressing misconceptions regarding medication use, both in relation to their harms and benefits.
Categorising Medication Safety
In response to the well documented thalidomide tragedy in the 1960s, in which more than 10,000 children were born worldwide with major birth defects, the Australian Government heart defects. 14 However, it is extremely uncommon for a medication to be given a less restrictive category based on the emergence of new (and often reassuring) evidence.
Rarely do the categorisations take into account important aspects like timing, dose, and route of exposure. For example, tetracycline are listed as category D, despite being safe to use during the first 18 weeks of pregnancy (16 weeks postconception) after which they may affect the formation of the baby's teeth and cause discolouration. 11 The opposite can also occur, with the combination of amoxicillin and clavulanic acid listed as category B1, suggesting safety throughout pregnancy, but clinical recommendations advise against the use of this medication in women with premature rupture of the membranes as there may be an increased risk of neonatal necrotising enterocolitis. 15 As such, blanket reference to categories alone is potentially misleading and could create unnecessary concern or harm.
Reference to categories alone also fails to acknowledge the background risk of adverse pregnancy outcomes associated with all pregnancies, irrespective of medication exposure.
This level of risk will differ according to other factors such as maternal smoking, advanced maternal age and co-morbidities (e.g. maternal overweight/obesity, pre-existing medical conditions). Understanding these factors is essential in identifying if medications increase the risk of adverse outcomes above the background risk, and what any absolute increase in risk actually is.
Additional concerns relate to confusion generated from a misunderstanding of key differences between the Australian and US classification system, which are similar, but not interchangeable. Many are also of the erroneous belief that the pregnancy categories apply to lactation, which is not the case. 12 Currently, there is no standardised endorsed approach towards the classification of medication use in lactation, although, different approaches are in use and will be commonly referenced by healthcare professionals. As with pregnancy categories, there should be a focus on individuals utilising their knowledge of underlying principles and available evidence to generate rational decisions, rather than use of categories alone.
Regrettably, current categories alone are not the only source of misleading information, with information provided in Product Information (PI) also the subject of much criticism for being overly cautious in nature, often listing medication use in pregnancy and lactation under special precautions or contraindications. 12 Such misleading information can often be further compounded by information obtained from the internet and lay sources.
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Changes to Categorising Medication Safety
Concerns around the use of pregnancy categories are not unique to the Australian landscape. Since 2008, the Federal Drug Administration (FDA) has taken significant steps towards major revisions to the labelling of prescription medications to allay such concerns.
These changes incorporate the inclusion of a narrative labelling model, placing discussions regarding medication use in the context of the background risk of adverse outcomes, summarising how documented risks were identified (i.e. human vs. animal studies) and providing more information on clinical considerations such as medication dosing (where available). 17 These changes are in the final stages of approval and will be gradually introduced over coming years, starting with newly listed medications. Only time will tell whether this change leads to improvements in the rational use of medications in pregnancy and lactation, and whether Australia introduces a similar labelling model. Pharmacists must use their expertise to look beyond these letters and numbers and make a more qualified assessment of the true benefits and risks. Evidence-based guides are available to assist in the critical appraisal and interpretation of research findings, 18 and numerous references are available for providing detailed information ( Table 1) . In most cases, however, it is not always about having the answer, but rather knowing where to look.
Potentially underused key resources are the specialist pregnancy and lactation medicines information services that exist across Australia, as well as overseas. Such Australian services differ greatly in respect to being limited to answering from healthcare professionals, while others also answer queries from the general public. Some services such as MotherSafe, also offer a number of fact sheets covering common queries in pregnancy and lactation that are able to be downloaded from their website. The receipt of sufficient funding to maintain the viability, reach and quality of these services is a consistent struggle within Australia, as well as internationally. In the current culture of centralisation, there is a concern that local specialist medicines information services could slowly be eroded, with the potential to negatively impact on service delivery and health outcomes.
Pharmacist Education
While pharmacists have recognised specialist knowledge on medications; including mechanisms of action, pharmacokinetics, clinical application of evidence, and assessment of adverse events, how well does this translate into areas of medication use in pregnancy and lactation?
In the United States, concerns have been raised that current undergraduate pharmacy curricula are lacking in providing students with sufficient information on medication use in pregnancy and lactation. 19, 20 While the delivery approach differs from standalone courses to the incorporation of content within other courses (i.e. pharmacology, pharmacokinetics), 59%
of respondents from 81 schools/colleges of pharmacy felt that their current approach did not adequately cover this material. 19 No data are available from an Australian perspective, but would be of interest.
Such limitations with undergraduate education can have important implications for future clinical practice. For example, previous studies have demonstrated that pharmacists often do not feel adequately equipped to provide information on medication use in pregnancy and/or lactation. 21 Further, when information is provided, it is not necessarily evidence-based and at times, inaccurate and based on their own opinions. 21 While it is recognised that in a relatively evidence-free zone it can be difficult to separate personal experiences and anecdotes from fact, pharmacists should be able to integrate available information with their medication expertise, to make appropriate individual risk/benefit decisions.
Notably, a recent survey undertaken to investigate the perspectives of community pharmacists in Australia on medication use and safety in breastfeeding identified that the majority of respondents (92%) were confident about supplying or counselling on medication during breastfeeding. 22 Remarkably, however, over one-third were unaware that ibuprofen and metronidazole are compatible with breastfeeding, with a number of pharmacists providing advice to women to stop breastfeeding. 22 This provides evidence that confidence is not always a good measure of competence.
Optimising Therapeutic Outcomes
Traditionally, investigating outcomes associated with medication use during pregnancy and lactation has tended to focus on safety, rather than efficacy. Pharmacists can play a greater role in optimising outcomes through various approaches, including; improved decision making on medication use at the point of prescribing, medication counselling (including adherence support) to address misconceptions, and therapeutic drug monitoring (TDM).
Intervening at the point of prescribing/dispensing is likely to have the greatest impact, but is not always achievable. Similarly, contributing towards decisions prior to, rather than during, pregnancy is ideal. Provision of medication counselling can provide significant benefits in correcting misperceptions, allaying fears, and hopefully improve medicationtaking behaviour. An aspect not well investigated is the role of Home Medicines Reviews (HMRs) or Outpatient pharmacy services in contributing towards improvements in rational medication use.
Despite awareness of alterations in pharmacokinetics during pregnancy, for many medications which have a wide therapeutic index, the clinical relevance of alterations in pharmacokinetics in pregnancy remains unclear. For medications which have a narrow therapeutic index, monitoring would be expected regardless of pregnancy status.
Understanding how pregnancy impacts on pharmacokinetics is essential in making sounds judgements relating to TDM (i.e. aminoglycoside/antiepileptic drugs dosing). 16 Further, there is still much work to be done and a significant role for pharmacists in determining the relevance of TDM programs and whether measuring drug concentrations during pregnancy ultimately improves outcomes beyond that already achieved through clinical judgement alone.
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Outcome Evaluation
While working in an area with much ambiguity can present many challenges for evidence-based practice, it offers many exciting possibilities for pharmacists to generate new evidence to guide best practice. Furthermore, many situations associated with medication use in pregnancy and/or lactation are unintentional or unavoidable. Integration of research within the clinical practice setting is essential in driving improvements in patient care and health outcomes and should be viewed as a core role for pharmacy practice. there needs to be greater emphasis on the importance of presenting, publishing, interpreting and translating new evidence into practice as it is generated. 24 Such endeavours are likely to benefit from greater training of pharmacists in research methods, 23 and the improved collaboration, coordination and exchange of information between treatment/research settings.
Future Directions
Facilitating improvements in pharmacist's contributions towards optimising medication management during pregnancy and lactation is likely to be multifactorial. There is a need for an assessment of the quality of undergraduate and postgraduate education as it pertains to medication use in pregnancy and lactation to ensure graduates and practicing pharmacists are adequately prepared to meet current and future demands. The formation of standards of practice and advanced pharmacy practice frameworks would assist in outlining key practice responsibilities, establishing core competency levels, and providing clear opportunities for career progression. An overview of such core pharmacist responsibilities and associated examples of practice are provided in Table 2 pharmacists, but also those representing key end users such as doctors and consumers.
In conclusion, this practice review provides a unique perspective on the role that pharmacists can play in optimising medication management during pregnancy and lactation.
It is anticipated that the summary of key references will become an invaluable resource in assisting pharmacists in obtaining the best available evidence, while it is also hoped that highlighting key components of practice through which pharmacists can contribute to improved health outcomes may provide impetus for the future development of formal standards of practice to drive improvements in clinical practice. Clinical pharmacy services will remain an integral part of the care of pregnant patients, especially as the obstetric population ages and has an increase in comorbid conditions, such as diabetes, heart disease and hypertension. 4 The pharmacy profession needs to be ready and willing to accept this challenge and should be keen to adapt to enhanced roles. • Contributing towards therapeutic decision making by obtaining an accurate and complete medication history, and assessing current medication management.
Recognising that medication use during pregnancy/lactation is common and that more women are entering pregnancy with pre-existing medical conditions • Utilising their specialist knowledge (pertaining to pharmacokinetic and therapeutic evidence of medication use during pregnancy and lactation) to improve selection, monitoring, and evaluation of individual medication treatments as part of the medication management plan.
Describing the pathophysiology of pregnancy/lactation specific conditions and their associated management
• Obtaining accurate evidence, regardless of the setting, regarding the associated benefits and risks of medication use in pregnancy and lactation and to ensure that such evidence is effectively communicated to women and their treating health professionals
Knowledge and appropriate use of key evidence-based references and guidelines relating to medication use during pregnancy and lactation
• Contributing towards an enhanced understanding of the condition and its associated treatment, with the objective of promoting self-management of the underlying condition (where applicable), and adherence to the medication treatment regimen.
Providing education and advice regarding importance of medication adherence and management of underlying disease (e.g. asthma) during pregnancy
Provision of ongoing medication management
Pharmacists are responsible for:
• Developing medication management plans and reviewing clinical progress, including investigating whether undesirable or unintended clinical effects may be related to medication treatment.
Identifying side effects in the infant which may be associated with use of specific medications taken during late gestation or lactation • Initiating monitoring and intervention, including assessment of whether medication treatment is achieving therapeutic goals, and the recommendation for therapeutic drug monitoring where indicated.
Recommending therapeutic drug monitoring of medications known to be subject to alterations in pharmacokinetics during pregnancy • Ensuring therapeutic drug monitoring, where indicated, is performed appropriately and for the provision of advice regarding interpretation of results and its implications for medication management.
Interpreting laboratory tests and providing recommendations for treatment alterations and further monitoring
